CureVac Gets $85 Million in EU Funding for Vaccine Production

CureVac has secured $85 million from the European Investment Bank for the development and large-scale production of vaccines, including its mRNA COVID-19 vaccine candidate.

The German drugmaker said the funding will go toward completing its new mRNA production facility in Tübingen, Germany.

CureVac began a phase 1 clinical trial of its COVID-19 vaccine candidate last month.